A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
VIVOS INC Precision Radionuclide Therapy™ (PRnT™)
Vivos Inc. is a medical device company with its patented Precision Radionuclide Therapy™.
Vivos Inc.
The Next Generation Cancer Treatment
RadioGel® for Human Cancer
RadioGel® is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT™). RadioGel® is a hydrogel liquid containing yttrium-90 phosphate micro-particles that may be administered directly into a tumor
Precision Radionuclide Therapy™ (PRnT™)
Our patented Precision Radionuclide Therapy™ (PRnT™) is the future of radionuclide cancer treatment – the insertion of our radionuclide device directly into the tumor tissue.
IsoPet® for Animal Cancer
IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT™). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.
Research Papers
Research Papers
Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite
Published online 2020 Feb 5
Darrell R. Fisher,1 Janean Fidel,2 and Charles A. Maitz3
IDE Submission
Research Papers
IDE Submission
IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy.
Press Releases
Research Papers
IDE Submission
Press Releases - Vivos Inc.
GlobeNewsWire has a list of all press releases and is the only place for the most accurate and up to date information on our revolutionary cancer treatment - Precision Radionuclide Therapy™ (PRnT™)
Investor Relations
We are trading under the OTCQB: RDGL and value our very loyal shareholders and followers and strive to have the most accurate and up to date information on our stock information.
SEC Filings
We are pleased to provide the following the most up to date SEC filings through www.sec.gov
Vivos Inc. Articles
Vivos Inc. Articles
We are pleased to provide you with our Quarterly Reports
Press Release December 26, 2024
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Cl
(Richland, WA – December 26, 2024) – Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet® Animal Cancer Division, setting new milestones in veterinary cancer care, and expanding its network of certified clinics across the U.S.
Press Release December 23, 2024
Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinic
(Richland, WA– December 23, 2024)– Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five patients with cancerous lymph nodes, represents a transformative step in advancing innovative cancer therapies. This clinical trial closely aligns with the protocol designed for Vivos’ planned study at the Mayo Clinic in the United States. In the initial phase, five patients with cancerous nodes in the neck have been successfully treated, with a primary focus on demonstrating the therapy’s safety. Imaging has confirmed precise placement of the RadioGel® treatment, and the patients are currently recovering well without complications.